Imugene Receives PD1-VAXX Ethics Trial Approval in USA
Filed with ASX · · 2 pages · English
Story so far
Earlier from Imugene
- Appendix 4E & Annual Report to shareholders
- Imugene Receives Third PD1-VAXX Ethics Trial Approval
- Imugene Receives Clinical Guidance from US FDA for Vaxinia
- Imugene Receives Second PD1-VAXX Ethics Trial Approval
- Imugene Receives Ethics Approval to Start PD1-VAXX Trial
Later from Imugene
- Imugene Secures $5.7 million Option Underwriting Agreement
- Imugene Immunotherapy Combination Patent Granted in US
- Imugene Receives FDA IND Approval for PD1-VAXX Trial in USA
- Imugene HER Vaxx shows positive Overall Survival in trial
- Imugene First Patient Dosed in PD1-VAXX Clinical Trial
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene